Medibank (ASX:MPL) share price up as customers get millions in support

Medibank is giving some of the money it's saved during COVID-19 lockdowns back to its customers. We take a closer look

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Medibank Private Ltd (ASX: MPL) recovered from a poor start this morning following news the company will be returning around $105 million to its customers.

At the time of writing, the Medibank share price is $3.16 – 0.48% higher than its previous close.

For comparison, the S&P/ASX 200 Index (ASX: XJO) is down 0.67% right now.

Let's take a look at today's news from the healthcare and health insurance company.

elderly woman cheers in doctor's office

Image source: Getty Images

Medibank's COVID-19 support

Medibank has announced it will be returning $105 million in COVID-19 net claims savings. Around 2 million of its customers will be eligible for the give back.

Medibank customers with extras-only policies will receive up to $52, while those holding hospital and extras policies could get $175.

It will also be postponing premium increases for 6 months.

Additionally, ahm customer extra limits will be extended by a year as many customers couldn't use their extras during COVID-19 lockdowns.

The give back will be funded through a partial release of the savings Medibank made when customers were forced to defer their claims because of COVID-19.

Australian Medibank and ahm customers who held policies between 1 July 2020 and 30 June 2021 are eligible for the support. Most customers will receive the financial support by the end of September.

The company has now handed out $300 million worth of COVID-19 support.

Medibank doesn't expect COVID-19 to impact its operating earnings for the 2021 financial year.

Commentary from management

Medibank's CEO David Koczkar said of the company's financial support package:

We've been there for our customers to help them navigate through this challenging time, and this give back is just another example of how we are supporting our customers…

We said right from the start of the pandemic that we would not profit from COVID-19, and that we were committed to returning any COVID-19 savings back to our customers because it is the right thing to do. And today's announcement shows that we have done what we said we would.

Medibank Private share price snapshot

Lately, the Medibank share price has been performing well on the ASX. It's currently 4% higher than it was at the start of 2021. It has also gained 7% since this time last year.

The company has a market capitalisation of around $8.6 billion, with approximately 2.7 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »